In a patient with a 7‑day history of cough, cold and fever who completed a 7‑day course of co‑amoxiclav (amoxicillin/clavulanic acid) 625 mg and still has a low‑grade fever after 2 days, what treatment should be given?

Switch to a Macrolide Antibiotic for Atypical Pathogen Coverage

For a patient who completed 7 days of co-amoxiclav 625mg for cough, cold, and fever but still has low-grade fever 2 days post-treatment, switch to a macrolide antibiotic (azithromycin 500mg once daily for 3 days OR clarithromycin 500mg twice daily for 5-7 days) to cover atypical bacteria such as Mycoplasma pneumoniae and Chlamydia pneumoniae. 1, 2, 3

Clinical Reasoning

The persistence of low-grade fever after completing an appropriate course of beta-lactam/beta-lactamase inhibitor combination suggests:

• Treatment failure with co-amoxiclav indicates the causative organism is likely not covered by this antibiotic
• Atypical bacteria (Mycoplasma pneumoniae, Chlamydia pneumoniae) are common causes of respiratory infections that do not respond to beta-lactams 1, 2
• These organisms lack cell walls, making them inherently resistant to all beta-lactam antibiotics including co-amoxiclav

Specific Treatment Algorithm

First-Line Switch Therapy:

• Azithromycin: 500mg once daily for 3 days (or 500mg day 1, then 250mg daily for days 2-5) 1
• Clarithromycin: 500mg twice daily for 5-7 days 1, 2

When to Consider Alternative Approaches:

If patient has worsening symptoms or high-risk features:

• Respiratory fluoroquinolone (levofloxacin 500mg once daily or moxifloxacin 400mg once daily) provides coverage for both typical and atypical pathogens 1, 2
• This is particularly important if pneumonia is suspected

If patient remains stable with only low-grade fever:

• Macrolide monotherapy is appropriate 3
• Reassess after 48 hours of macrolide therapy 3

Critical Reassessment Points

Before switching antibiotics, verify:

1. This is truly bacterial infection - not viral illness with prolonged fever course
2. No pneumonia present - obtain chest X-ray if:
   • Respiratory rate >30 breaths/min
   • Significant dyspnea
   • Abnormal lung auscultation 1
3. No complications - rule out empyema, abscess, or other suppurative complications 1

Common Pitfalls to Avoid

Do NOT simply extend co-amoxiclav duration - if 7 days failed, continuing the same antibiotic is unlikely to succeed and increases resistance risk 3, 4

Do NOT add a macrolide to ongoing co-amoxiclav unless there is documented pneumonia requiring dual coverage 3

Do NOT assume all persistent fever requires antibiotics - recent evidence shows antibiotics have no measurable impact on duration or severity of acute bronchitis in many cases 5. However, given this patient already received 7 days of treatment, switching to cover atypical organisms is reasonable.

Expected Response Timeline

• Improvement should occur within 48 hours of starting macrolide therapy 3
• If no improvement after 48 hours on macrolide: Consider hospitalization for further evaluation including chest imaging, blood cultures, and possible bronchoscopy 1
• Complete resolution may take 5-7 days even with appropriate therapy 3

Special Considerations

The European Respiratory Society guidelines emphasize that assessment of response should occur at day 5-7 of treatment 1. Since this patient completed 7 days and still has fever at day 9, this represents treatment failure requiring antibiotic modification rather than simple continuation.

French guidelines specifically note that amoxicillin failure after 48 hours suggests atypical bacteria justifying macrolide monotherapy 3, which directly applies to this clinical scenario where co-amoxiclav (amoxicillin-clavulanate) has failed after a full 7-day course.